Bio-Gene Technology Limited
BGT.AX
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.78M
Close$
$0.01
55% downside
Current Fair Value
55% downsideOvervalued by 55% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.78 Million |
|---|---|
| Enterprise Value | $1.84 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.01 |
| Beta | 0.79 |
| Outstanding Shares | 316,326,158 |
Return
| Return on Equity | -208.34% |
|---|---|
| Return on Assets | -166.86% |
| Return on Invested Capital | -261.56% |
Valuation & Multiples
| P/E Ratio | -1.87 |
|---|---|
| PEG | -2.82 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.34 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 28, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
March 3, 2027
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Bio-Gene Technology Limited
5 employees
CEO: Timothy Owen Grogan Bio-Gene Technology Limited, an agricultural technology firm based in Australia, focuses on the development and commercialization of insecticides and pesticides. These solutions are designed for a range of uses, encompassing animal healt...